Evidence-based focused review of management of hyperviscosity syndrome

Blood

Volumn 119, Issue 10, 2012, Pages 2205-2208

  Stone, Marvin J ^a   Bogen, Steven A ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN;

AGED; ANEMIA; BLURRED VISION; CASE REPORT; DISEASE SEVERITY; ELECTROPHORESIS; EPISTAXIS; EVIDENCE BASED PRACTICE; FATIGUE; HEADACHE; HUMAN; HYPERVISCOSITY SYNDROME; LABORATORY TEST; LYMPHADENOPATHY; MALE; PLASMA VISCOSITY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 84858009797     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-347690     Document Type: Review

References (38)

1. Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost. 2003;29:467-471. (Pubitemid 37352646)
2. Wells R. Medical intelligence. Current concepts: syndromes of hyperviscosity. N Engl J Med. 1970;283(4):183-186.
3. Atkins D, Eccles M, Flottrop S, et al. Grading quality of evidence and strength of recommendations: the GRADE Working Group. Br Med J. 2004;328(7454):1490-1498.
4. Crowther M, Chan YL, Garbett I, et al. Evidence based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood. 2011;118(15):4036-4040.
5. Dintenfass L. In: Blood Microrheology. Viscosity Factors in Blood Flow, Ischaemia and Thrombosis. New York, NY: Appleton Century-Crofts; 1971:41,326.
6. Phillips MJ, Harkness J. Plasma and whole blood viscosity. Br J Haematol. 1976;34:347-352.
7. Metzger H. Structure and function of gammaM macroglobulins. Adv Immunol. 1970;12:57-116.
8. MacKenzie MR, Babcock J. Studies of the hyperviscosity syndrome: II. Macroglobulinemia. J Lab Clin Med. 1975;85(2):227-234.
9. Waldenström J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia: a new syndrome? Acta Med Scand. 1944;117:217-247.
10. College of American Pathologists. 2010 V-A & V-B Participant Summary. Northfield, IL: College of American Pathologists; 2010.
11. Boroviczeny K, Dintenfass L, Fukada E, et al. Recommendation for a selected method for the measurement of plasma viscosity: International Committee for Standardization in Haematology. J Clin Pathol. 1984;37:1147-1152.
12. Stone MJ. Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):97-99.
13. Rosencranz R, Bogen SA. Clinical laboratory measurement of serum, plasma, and blood viscosity. Am J Clin Pathol. 2006;125(1):78-86.
14. Fahey JL, Barth WF, Solomon A. Serum hyperviscosity syndrome. JAMA. 1965;192(6):120-123.
15. Perry MC, Hoagland HC. The hyperviscosity syndrome. JAMA. 1976;236(4):392-393.
16. Bloch KJ, Maki DG. Hyperviscosity syndromes associated with immunoglobulin abnormalities. Semin Hematol. 1973;10(2):113-124.
17. MacKenzie MR, Lee TK. Blood viscosity in Waldenström's macroglobulinemia. Blood. 1977; 49(4):507-510.
18. MacKenzie MR, Brown E, Fudenberg HH, et al. Waldenström's macroglobulinemia: correlation between expanded plasma volume and increased serum viscosity. Blood. 1970;35(3):394-408.
19. Sigle JP, Buser A. Hyperviscosity syndrome. Blood. 2011;117(5):1446.
20. Stone MJ, Pascual V. Pathophysiology of Waldenström's macroglobulinemia. Haematologica. 2010;95:359-364.
21. Schwab PJ, Fahey JL. Treatment of Waldenström's macroglobulinemia by plasmapheresis. N Engl J Med. 1960;263(2):574-579.
22. Solomon A, Fahey JL. Plasmapheresis therapy in macroglobulinemia. Ann Intern Med. 1963;58(5): 789-800.
23. Stone MJ, Fedak JE. Studies on monoclonal antibodies: II. Immune complex (IgM-IgG) cryoglobulinemia: the mechanism of cryoprecipitation. J Immunol. 1974;113(4):1377-1385.
24. Waldenström JG, Raiend Ü. Plasmapheresis and cold sensitivity of immunoglobulin molecules. Acta Med Scand. 1984;216:449-466.
25. Della Rossa A, Tavoni A, Bombardieri S. Hyperviscosity syndrome in cryoglobulinemia: clinical aspects and therapeutic considerations. Semin Thromb Haemost. 2003;9(5):473-477. (Pubitemid 37352647)
26. Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379 (9813):348-360.
27. Stone MJ. Pathogenesis and morbidity of autoantibody syndromes in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11: 157-159.
28. Thomas EL, Olk RJ, Markman M, et al. Irreversible visual loss in Waldenström's macroglobulinaemia. Br J Ophthalmol. 1983;67:102-106. (Pubitemid 13174345)
29. Menke MN, Feke GT, McMeel JW, et al. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):100-103.
30. Buskard NA, Galton DA, Goldman JM, et al. Plasma exchange in the long-term management of Waldenström's macroglobulinemia. Can Med Assoc J. 1977;117:135-137. (Pubitemid 8166819)
31. Ballestri M, Ferrari F, Magistroni R, et al. Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guidelines study. Ann Ist Super Sanita. 2007;43(2):171-175.
32. Frase LL, Stone MJ. Long-term survival in Waldenström's macroglobulinemia. Am J Med. 1998; 104:507-508.
33. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol. 2002;20(9):2327-2333.
34. Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2009;114(12):2375-2385.
35. Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85(9):824-833.
36. Yang G, Xu L, Hunter Z, et al. The rituximab and IVIG related IgG flare in Waldenström's macroglobulinemia is associated with monocytic activation of FCGRIIA signaling, and triggering of IL-6 release by the PI3K/AKT and MAPK pathways [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 2870.
37. Capra JD, Kunkel HG. Aggregation of gammaG3 proteins: relevance to the hyperviscosity syndrome. J Clin Invest. 1970;49:610-621.
38. Pope RM, Mannik M, Gilliland BC, Teller DC. The hyperviscosity syndrome in rheumatoid arthritis due to intermediate complexes formed by selfassociation of IgG rheumatoid factors. Arthritis Rheum. 1975;18(2):97-106.